SUMMARY: Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 316,950 new cases of female breast cancer will be diagnosed in 2025, and about 42,170 women will die of the disease, largely due to metastatic recurrence.
Background
Postmastectomy radiation therapy (PMRT) remains a cornerstone of curative-intent treatment for many patients with invasive breast cancer, significantly reducing the risk of locoregional recurrence (LRR) and improving Disease-Specific Survival. However, with evolving systemic therapies, less extensive axillary surgery, and modern radiation techniques, the benefit of PMRT now varies widely across patient subgroups. Recognizing the need to update clinical decision-making in this context, the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and Society of Surgical Oncology (SSO) have released a comprehensive new guideline to replace the 2016 version.
The new recommendations jointly published in Journal of Clinical Oncology, Practical Radiation Oncology, and Annals of Surgical Oncology provide refined guidance on when and how PMRT should be applied in both upfront surgical and post-neoadjuvant settings.
Development and Scope
A multidisciplinary task force representing Radiation, Medical, and Surgical Oncology collaborated with experts from the European Society for Radiotherapy and Oncology. The group conducted a systematic review of evidence published between 2005 and 2024 and used structured consensus methods to determine recommendation strength and evidence quality.
The guideline addresses four primary clinical domains:
- Indications for PMRT after upfront mastectomy.
- Indications for PMRT following Neoadjuvant Systemic Therapy (NAST).
- Appropriate treatment volumes and dose-fractionation schedules.
- Optimal delivery techniques and normal tissue sparing strategies.
The recommendations are intended for adult patients with breast cancer undergoing mastectomy and are directed toward Radiation, Surgical, and Medical Oncologists, as well as other oncology professionals involved in multidisciplinary breast cancer management.
Key Recommendations
- PMRT After Upfront Mastectomy
- Node-positive disease: PMRT is strongly recommended for most patients with pathologically positive axillary lymph nodes to reduce recurrence and breast cancer–specific mortality.
- pT4 tumors: Strong recommendation for PMRT regardless of nodal status.
- pT3N0 tumors: PMRT is conditionally recommended; omission or volume reduction may be appropriate when clinicopathologic features are favorable.
- pT1–2N0 tumors: PMRT is generally not recommended but may be considered in the presence of multiple high-risk factors (e.g., triple-negative biology, LVI, young age, high grade, or central/medial tumor location).
- Positive margins: In patients with positive surgical margins but no other PMRT indication, treatment limited to the chest wall or reconstructed breast alone is conditionally advised.
- PMRT After Neoadjuvant Systemic Therapy
- Locally advanced disease (cT4 or cN2–3): PMRT is strongly recommended irrespective of pathologic response.
- Residual nodal disease (ypN+): Strong recommendation for PMRT to the chest wall and regional nodes.
- Pathologic complete response (ypN0) after cT1–3N1 or cT3N0 disease: PMRT is conditionally recommended for patients with high-risk features (young age, lymphovascular invasion, high residual cancer in breast); omission may be appropriate for select patients with favorable features.
- cT1–2N0 disease with ypN0 response: PMRT is generally not indicated unless multiple high-risk factors are present such as young age, lymphovascular invasion, and high residual cancer in breast.
- Positive post-neoadjuvant margins: PMRT is strongly recommended.
- Treatment Volumes and Dose-Fractionation
- Target volumes: Irradiation should encompass the ipsilateral chest wall or reconstructed breast and regional lymphatics (axillary, supraclavicular, and internal mammary nodes). For selected pT3N0 cases, chest wall treatment alone or reconstructed breast alone may be reasonable.
- Internal mammary coverage: Should be individualized based on tumor location, nodal burden, and risk features.
- Fractionation: Moderate hypofractionation is preferred for most patients, including those with reconstruction, while conventional fractionation remains acceptable in select circumstances.
- Boost therapy: A boost to the chest wall or scar may be considered for patients with T4 disease or close/positive margins. A nodal boost is recommended when residual nodal disease is suspected and surgical clearance is incomplete.
- Recommended Techniques for PMRT Delivery
- Planning and delivery: CT-based volumetric planning using 3-dimensional conformal radiation therapy (3D-CRT) is the standard approach.
- Advanced modalities: Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) is advised when 3D-CRT cannot meet dosimetric goals; daily image guidance is recommended.
- Cardiopulmonary sparing: Deep inspiration breath hold (DIBH) should be used whenever it reduces dose exposure to the heart and lungs, supported by real-time monitoring and image verification.
- Bolus use: Routine use of tissue-equivalent bolus is not recommended. However, bolus may be selectively applied in cases with skin involvement, positive superficial margins, dermal lymphatic invasion, or extensive lymphovascular invasion.
Implementation Considerations
The guideline emphasizes individualized, multidisciplinary decision-making that weighs recurrence risk against treatment-related toxicities.
- For patients with limited nodal disease (e.g., T1–2N1), omission of PMRT may be reasonable if the expected absolute benefit is low.
- Patient preferences and quality-of-life considerations should inform discussions, especially regarding reconstructive implications and late toxicity risks.
- The recommendations endorse shared decision-making across disciplines, highlighting the importance of coordinated care between surgeons, radiation oncologists, and medical oncologists.
Clinical Perspective
The expert panel acknowledged that radiation therapy after mastectomy can meaningfully reduce recurrence and improve survival, but the benefit must be balanced with the individual’s disease profile and values. The update also acknowledges persistent evidence gaps, particularly regarding patients who achieve nodal pathologic complete response after neoadjuvant therapy, underscoring the need for ongoing prospective research.
Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline. Jimenez RB, Abdou Y, Anderson P, et al. J Clin Oncol, 2025;43:3292-3311
